Dublin, July 21, 2016 (GLOBE NEWSWIRE) -- Research and Markets has announced the addition of the "Pharma's Patient Centricity" report to their offering. Many in the industry agree that patient centricity is a business imperative, but it is unclear precisely what it means in business or organizational terms, and less clear still how to achieve it within the pharmaceutical industry. Patient centricity is not a function, but a mindset, a new way of doing R&D and of conceiving of therapeutic solutions. There are multiple forces driving greater patient centricity. These include payers' focus on outcomes, the need for product differentiation, new digital technologies and data sources, advances in genomics and personalized medicines, and the empowered consumer. But there are as many hurdles, not least the lack of a roadmap as to how to be patient-centric, the lack of standards around patient-centric data and processes, regulatory uncertainties, disciplinary silos, and engrained attitudes clinging to traditional metrics and approaches to drug development. This report addresses: - Drivers and resistors of patient centricity - Patient centricity in practice - Patient centricity impact on organizations and cultures - Selected case studies along the value chain Key Topics Covered: Executive Summary 1. Drivers and resistors of patient centricity
2. Patient centricity in practice
3. Patient centricity means changing organizations and cultures
4. Selected case studies along the value chain Drivers and Resistors of Patient Centricity 5. Patient centricity is more mindset than process
6. Drivers and resistors
7. Drivers
8. Resistors
9. Bibliography Patient Centricity in Practice 10. From discovery to commercialization
11. Bibliography Patient Centricity Means Changing Organisations and Cultures 12. New ways of thinking
13. Changing the language
14. Top-down and bottom-up leadership
15. Lessons from other industries
16. Technology enables patient centricity and demands new treatment paradigm
17. Focus on outcomes, business will follow
18. Patient centricity playbooks are emerging
19. Bibliography Selected Case Studies Along the Value Chain 20. UCB: re-organizing around patients
21. Sanofi: diffusing patient-centric innovation
22. LEO Pharma: leading the pack in patient centricity
23. Actelion: new approaches to patient-relevant trial measures
24. AstraZeneca: engaging patients in research
25. Novo Nordisk: a patient-centric heritage
26. Shire: spreading patient centricity beyond rare diseases
27. Bibliography
For more information visit http://www.researchandmarkets.com/research/t9...as_patient
CONTACT: Research and Markets Laura Wood, Senior Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Sector: Pharmaceuticals
